BTF NICE guideline info day

[loueldhen]

Videos are available for the event held on 8th Feb.

btf-thyroid.org/news/thyroi...

[pennyannie]

Hello Loueldhen

Thank you so much for bringing this meeting to my attention.

I think I've now listened to all the speeches and read most of the visuals and just feel totally disappointed : I have been left with an overwhelming feeling of having learnt nothing and simply don' t understand the point of these meetings other than for those on the platform.

I don't know if there was a filmed session that was open to the floor audience to question the speakers, maybe I missed it ?

Just so glad I didn't go, as from Cornwall, it would have been very expensive and pointless.

[loueldhen in reply to pennyannie]

Not too bad for me from East Sussex. When I booked I thought I was going to be educated. When I was there I realised it was the other way round. Several of the speakers had never had contact with patients before. It can only bring benefit.

I got most out of David Halsall’s talk. There were questions and you could ask questions but not much was revealed. I put precis of all speeches and questions on the itt fb page. There was also the opportunity to speak to the speakers.

[pennyannie in reply to loueldhen]

Well I'm glad it wasn't just ' me ' then !!

[Hidden]

Thanks for the link, I like the advice for patients still symptomatic on levo. The advice is there’s no good evidence for T3 or NDT so

“If symptoms persist consider adjusting dose (of T4) to achieve optimal wellbeing

1. Avoid doses that cause TSH suppression

2. Check 3 monthly until stable then once yearly

3 Consider measuring fT4 and TSH if continued symptoms”

So that’s all nicely resolved then, all of you guys with symptoms just need to sort your T4 dose and all will be well. That earth shattering insight into the solution for patients with persistent symptoms has really restored my confidence that I’ll finally get better.

[loueldhen in reply to Hidden]

1.3.4 says do not routinely offer liothyronine - it does not rule it out. Our main problem is with CCGs that extend this to proscribe liothyronine and therefore remove all clinical judgement from endos. The guidelines have nothing to offer the 10-20% of patients who do not do well on levothyroxine treatment.

[Hidden in reply to loueldhen]

The guidelines simply acknowledge that some people continue to have symptoms and then offers nothing